Intravenous immunoglobulins as a treatment for alzheimers disease: Rationale and current evidence

Richard Dodel, Frauke Neff, Carmen Noelker, Refik Pul, Yansheng Du, Michael Bacher, Wolfgang Oertel

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Current treatment options for Alzheimers disease (AD) exert only a short-lived effect on disease symptoms. Active and passive immunotherapy have both been shown to be effective in clearing plaques, removing β-amyloid (Aβ) and improving behaviour in animal models of AD. Although the first active immunization trial in humans was discontinued because of severe adverse effects, several new approaches are currently being investigated in clinical trials. Recently, commercially available intravenous immunoglobulins (IVIG) have been used in small pilot trials for the treatment of patients with AD, based on the hypothesis that IVIG contains naturally occurring autoantibodies (nAbs-Aβ) that specifically recognize and block the toxic effects of Aβ. Furthermore, these nAbs-Aβ are reduced in AD patients compared with healthy controls, supporting the notion of replacement with IVIG. Beyond the occurrence of nAbs-Aβ, evidence for several other mechanisms associated with IVIG in AD has been reported in preclinical experiments and clinical studies. In 2009, a phase III clinical trial involving more than 360 AD patients was initiated and may provide conclusive evidence for the effect of IVIG as a treatment option for AD in 2011. In this article, we review the current knowledge and scientific rationale for using IVIG in patients with AD and other neurodegenerative disorders.

Original languageEnglish
Pages (from-to)513-528
Number of pages16
JournalDrugs
Volume70
Issue number5
DOIs
StatePublished - 2010

Fingerprint

Intravenous Immunoglobulins
Alzheimer Disease
Therapeutics
Active Immunotherapy
Phase III Clinical Trials
Passive Immunization
Poisons
Amyloid Plaques
Neurodegenerative Diseases
Autoantibodies
Vaccination
Animal Models
Clinical Trials

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Intravenous immunoglobulins as a treatment for alzheimers disease : Rationale and current evidence. / Dodel, Richard; Neff, Frauke; Noelker, Carmen; Pul, Refik; Du, Yansheng; Bacher, Michael; Oertel, Wolfgang.

In: Drugs, Vol. 70, No. 5, 2010, p. 513-528.

Research output: Contribution to journalArticle

Dodel, Richard ; Neff, Frauke ; Noelker, Carmen ; Pul, Refik ; Du, Yansheng ; Bacher, Michael ; Oertel, Wolfgang. / Intravenous immunoglobulins as a treatment for alzheimers disease : Rationale and current evidence. In: Drugs. 2010 ; Vol. 70, No. 5. pp. 513-528.
@article{561cdeb3a68a458db20d8b570cc2adcb,
title = "Intravenous immunoglobulins as a treatment for alzheimers disease: Rationale and current evidence",
abstract = "Current treatment options for Alzheimers disease (AD) exert only a short-lived effect on disease symptoms. Active and passive immunotherapy have both been shown to be effective in clearing plaques, removing β-amyloid (Aβ) and improving behaviour in animal models of AD. Although the first active immunization trial in humans was discontinued because of severe adverse effects, several new approaches are currently being investigated in clinical trials. Recently, commercially available intravenous immunoglobulins (IVIG) have been used in small pilot trials for the treatment of patients with AD, based on the hypothesis that IVIG contains naturally occurring autoantibodies (nAbs-Aβ) that specifically recognize and block the toxic effects of Aβ. Furthermore, these nAbs-Aβ are reduced in AD patients compared with healthy controls, supporting the notion of replacement with IVIG. Beyond the occurrence of nAbs-Aβ, evidence for several other mechanisms associated with IVIG in AD has been reported in preclinical experiments and clinical studies. In 2009, a phase III clinical trial involving more than 360 AD patients was initiated and may provide conclusive evidence for the effect of IVIG as a treatment option for AD in 2011. In this article, we review the current knowledge and scientific rationale for using IVIG in patients with AD and other neurodegenerative disorders.",
author = "Richard Dodel and Frauke Neff and Carmen Noelker and Refik Pul and Yansheng Du and Michael Bacher and Wolfgang Oertel",
year = "2010",
doi = "10.2165/11533070-000000000-00000",
language = "English",
volume = "70",
pages = "513--528",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "5",

}

TY - JOUR

T1 - Intravenous immunoglobulins as a treatment for alzheimers disease

T2 - Rationale and current evidence

AU - Dodel, Richard

AU - Neff, Frauke

AU - Noelker, Carmen

AU - Pul, Refik

AU - Du, Yansheng

AU - Bacher, Michael

AU - Oertel, Wolfgang

PY - 2010

Y1 - 2010

N2 - Current treatment options for Alzheimers disease (AD) exert only a short-lived effect on disease symptoms. Active and passive immunotherapy have both been shown to be effective in clearing plaques, removing β-amyloid (Aβ) and improving behaviour in animal models of AD. Although the first active immunization trial in humans was discontinued because of severe adverse effects, several new approaches are currently being investigated in clinical trials. Recently, commercially available intravenous immunoglobulins (IVIG) have been used in small pilot trials for the treatment of patients with AD, based on the hypothesis that IVIG contains naturally occurring autoantibodies (nAbs-Aβ) that specifically recognize and block the toxic effects of Aβ. Furthermore, these nAbs-Aβ are reduced in AD patients compared with healthy controls, supporting the notion of replacement with IVIG. Beyond the occurrence of nAbs-Aβ, evidence for several other mechanisms associated with IVIG in AD has been reported in preclinical experiments and clinical studies. In 2009, a phase III clinical trial involving more than 360 AD patients was initiated and may provide conclusive evidence for the effect of IVIG as a treatment option for AD in 2011. In this article, we review the current knowledge and scientific rationale for using IVIG in patients with AD and other neurodegenerative disorders.

AB - Current treatment options for Alzheimers disease (AD) exert only a short-lived effect on disease symptoms. Active and passive immunotherapy have both been shown to be effective in clearing plaques, removing β-amyloid (Aβ) and improving behaviour in animal models of AD. Although the first active immunization trial in humans was discontinued because of severe adverse effects, several new approaches are currently being investigated in clinical trials. Recently, commercially available intravenous immunoglobulins (IVIG) have been used in small pilot trials for the treatment of patients with AD, based on the hypothesis that IVIG contains naturally occurring autoantibodies (nAbs-Aβ) that specifically recognize and block the toxic effects of Aβ. Furthermore, these nAbs-Aβ are reduced in AD patients compared with healthy controls, supporting the notion of replacement with IVIG. Beyond the occurrence of nAbs-Aβ, evidence for several other mechanisms associated with IVIG in AD has been reported in preclinical experiments and clinical studies. In 2009, a phase III clinical trial involving more than 360 AD patients was initiated and may provide conclusive evidence for the effect of IVIG as a treatment option for AD in 2011. In this article, we review the current knowledge and scientific rationale for using IVIG in patients with AD and other neurodegenerative disorders.

UR - http://www.scopus.com/inward/record.url?scp=77949962484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949962484&partnerID=8YFLogxK

U2 - 10.2165/11533070-000000000-00000

DO - 10.2165/11533070-000000000-00000

M3 - Article

C2 - 20329802

AN - SCOPUS:77949962484

VL - 70

SP - 513

EP - 528

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 5

ER -